Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

All (animal) models (of neurodegeneration) are wrong. Are they also useful?

ABSTRACT: Richard M. Ransohoff, Entrepreneur-in-Residence at Third Rock Ventures and Visiting Scientist at Harvard Medical School, provides his personal opinion on using animal models to address current challenges and opportunities in drug development for neurodegeneration.

SUBMITTER: Ransohoff RM

PROVIDER: S-EPMC6279414 | biostudies-literature | 2018 Dec

REPOSITORIES: biostudies-literature

ACCESS DATA

Json Xml

Publications

All (animal) models (of neurodegeneration) are wrong. Are they also useful?

Ransohoff Richard M RM

The Journal of experimental medicine 20181120 12

Richard M. Ransohoff, Entrepreneur-in-Residence at Third Rock Ventures and Visiting Scientist at Harvard Medical School, provides his personal opinion on using animal models to address current challenges and opportunities in drug development for neurodegeneration. ...[more]

PMID: 30459159

Similar Datasets

Response to letter to the editor: "All models are wrong; some models are useful".

Project description: Not available

| S-EPMC7523438 | biostudies-literature

Scaling clearance in paediatric pharmacokinetics: All models are wrong, which are useful?

Project description: Not available

| S-EPMC5346879 | biostudies-literature

Wrong, but useful: regional species distribution models may not be improved by range-wide data under biased sampling.

Project description: Not available

| S-EPMC5817152 | biostudies-literature

Transgenic animal models of neurodegeneration based on human genetic studies.

Project description: Not available

| S-EPMC3084899 | biostudies-literature

Quality control gone wrong: mitochondria, lysosomal storage disorders and neurodegeneration.

Project description: Not available

| S-EPMC3976615 | biostudies-literature

Divalent metal transporter 1 (DMT1) contributes to neurodegeneration in animal models of Parkinson's disease.

Project description: Not available

| S-EPMC2587621 | biostudies-literature

Neurodegeneration in spinal muscular atrophy: from disease phenotype and animal models to therapeutic strategies and beyond.

Project description: Not available

| S-EPMC3955729 | biostudies-literature

GPR40 Agonist ameliorates neurodegeneration and motor impairment by regulating NLRP3 inflammasome in Parkinson’s disease animal models.

Project description:Parkinson's disease (PD) is characterized by the progressive degeneration of dopaminergic neurons in the substantia nigra pars compacta (SN) and accumulation of intracellular α-synuclein aggregates known as Lewy bodies and Lewy neurites. Levels of polyunsaturated fatty acids (PUFAs) are reduced in the SN of PD patients and G protein-coupled receptor 40 (GPR40) serves as a receptor for PUFAs, playing a role in neurodevelopment and neurogenesis. Additionally, GPR40 is implicated in neuropathological conditions such as apoptosis and inflammation, suggesting its potential as a therapeutic target in PD. In this study, we investigated the neuroprotective effects of the GPR40 agonist, TUG469, in PD models. Our results demonstrate that TUG469 reduces neurotoxicity induced by 6-OHDA in SH-SY5Y cells. In the 6-OHDA-induced PD model, TUG469 treatment improved motor impairment, preserved dopaminergic fibers and cell bodies in the striatum (ST) or SN, and attenuated 6-OHDA-induced microgliosis and astrogliosis in the brain. Furthermore, in a PD model involving the injection of mouse ɑ-syn fibrils into the brain (mPFFs-PD model), TUG469 treatment reduced the level of phosphorylated Ser129 ɑ-synuclein and decreased microgliosis and astrogliosis in mPFFs-PD model. Our investigation also revealed that TUG469 modulates inflammasome activation, apoptosis, and autophagy in the 6-OHDA-PD model, as evidenced by RNA-seq analysis and western blotting. In summary, our findings highlight the neuroprotective effects of GPR40 agonist on dopaminergic neurons and their potential as therapeutic agents for PD. These results underscore the importance of targeting GPR40 in PD treatment, particularly in mitigating neuroinflammation and preserving neuronal integrity.

2024-08-23 | GSE275257 | GEO

Impact of high iron intake on cognition and neurodegeneration in humans and in animal models: a systematic review.

Project description: Not available

| S-EPMC5914328 | biostudies-literature

Retinal Neurodegeneration: Correlation between Nutraceutical Treatment and Animal Model.

Project description: Not available

| S-EPMC7997156 | biostudies-literature